Vor Biopharma Inc.

Equities

VOR

US9290331084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 17/05/2024 am IST			5-day change	1st Jan Change
1.8 ^USD	+3.45%		-2.70%	-20.00%

13/05	Oppenheimer Adjusts Vor Biopharma Price Target to $10 From $15, Maintains Outperform Rating	MT
09/05	Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Vor Biopharma : ASH – 2023 – POSTER PRESENTATION – 4862

December 11, 2023 at 11:04 pm IST

December 11, 2023

ASH - 2023 - POSTER PRESENTATION - 4862

Download

VCAR33 (Allogeneic)

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Vor_ASH_Poster_VBP301-Trial-In-Progress-11.14.2023_final2

Download

Attachments

Original Link
Original Document
Permalink

Disclaimer

Vor Biopharma Inc. published this content on 11 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 December 2023 17:32:58 UTC.

Latest news about Vor Biopharma Inc.

Oppenheimer Adjusts Vor Biopharma Price Target to $10 From $15, Maintains Outperform Rating	13/05	MT
Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Vor Biopharma Inc. Appoints Fouad Namouni as Class II Director	03/05	CI
Stifel Cuts Price Target on Vor Biopharma to $12 From $15, Maintains Buy Rating	21/03	MT
Oppenheimer Cuts Vor Biopharma Price Target to $15 From $18, Maintains Outperform Rating	21/03	MT
Vor Biopharma Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03	CI
Vor Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
Vor Biopharma Doses First Blood Cancer Patient With Leukemia Treatment, Provides Cash Runway Guidance	18/01	MT
Vor Bio Doses First AML Patient with VCAR33	18/01	CI
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference	10/11	CI
Vor Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
Vor Bio Announces Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform	02/11	CI
Wedbush Cuts Vor Biopharma's Price Target to $11 From $18, Keeps Outperform Rating	11/23/11	MT
Vor Biopharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell Small Cap Comp Value Index	23/23/23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 3000 Index	23/23/23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 3000E Index	23/23/23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell Small Cap Completeness Index	23/23/23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2500 Index	23/23/23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2000 Index	23/23/23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 3000E Value Index	23/23/23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 3000 Value Index	23/23/23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2000 Value Index	23/23/23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2000 Dynamic Index	23/23/23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2500 Value Index	23/23/23	CI

Chart Vor Biopharma Inc.

Duration

Period

More charts

Company Profile

Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Companyâs lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.

Sector

Biotechnology & Medical Research

Calendar

20/05/2024 - H.C. Wainwright BioConnect Investor Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.8 USD

Average target price

14.06 USD

Spread / Average Target

+681.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VOR BIOPHARMA INC.	-20.00%	119M
MODERNA, INC.	+33.37%	49.46B
IQVIA HOLDINGS INC.	+1.55%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-4.22%	29.09B
ICON PUBLIC LIMITED COMPANY	+11.57%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	18.64B
BIO-TECHNE CORPORATION	+7.36%	13.16B
MEDPACE HOLDINGS, INC.	+28.30%	12.55B
UNITED THERAPEUTICS CORPORATION	+23.80%	12.1B

Other Biotechnology & Medical Research